The price of GRFS is predicted to go up -6.51%, based on the high correlation periods with BLMN. The similarity of these two price pattern on the periods is 95.16%.
GRFS
BLMN
Grifols is one of the leading producers of plasma products globally. Multiple products allow Grifols to use plasma efficiently, reducing production costs.
With technology that removes essentially all pathogens, plasma products are much safer than they were two decades ago and more affordable than recombinant counterparts.
Grifols' Prolastin dominates the market to treat a rare pulmonary disorder.